ZERO WORLD RESEARCHLiterature database on amino acids & organic acids

Modulation of the Antitumor Response to Metformin, Caffeine, and Sodium Dichloroacetate by the Hypoxic Microenvironment in Lung Cancer Cells.

International journal of molecular sciences2025Garcia-Martin MO, Castillejos-Lopez M, Prado-Garcia H, et al.
Study designOther primary literature
SubjectHuman

Record checks

Study design
Other primary literature
Subject
Human
Publication year
2025
Source
doi.org
Abstract display
Shown here
Publication status
Active
Status checked
17 Aug 2026
Collected
3 Aug 2026
Freshness
Current
Review stage
Automated
Record status
Published

Abstract

Metformin, caffeine, and dichloroacetate (DCA) have shown antitumor effects. The hypoxic tumor microenvironment can modulate drug response. We aimed to analyze the interaction of metformin with caffeine or DCA in lung cancer cells (HCC827) under normoxia and hypoxia conditions. Cell viability was evaluated using the crystal violet assay after individual and combined drug treatment under normoxia (21% O2) and hypoxia (1% O2) conditions. Combination effects were analyzed using isobolographic analysis. The results show that under normoxia conditions, the combination of metformin with DCA (γ = 0.98 ± 0.35, p > 0.05) or caffeine (γ = 0.90 ± 0.34, p > 0.05) revealed additivity. However, in hypoxia, both combinations exhibited significant antagonism, with γ values appearing greater than one for metformin + DCA (γ = 4.20 ± 1.44, p < 0.05) and metformin + caffeine (γ = 2.88 ± 0.90, p < 0.05). Hypoxia significantly alters the pharmacological interaction of metformin with caffeine or DCA, which could limit their combined therapeutic potential in hypoxic tumors despite metformin's activity in this environment. The importance of considering tumor oxygenation status in the design of combined therapies for lung cancer is emphasized.

MeSH

Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCaffeineCell HypoxiaCell Line, TumorCell SurvivalDichloroacetic AcidHumansLung NeoplasmsMetforminOxygenTumor Microenvironment

DOI 10.3390/ijms26115014

PMID 40507826

View source →